CMT1A Duplicated Region Transcript 15 pseudogene 1 (CDRT15P1)

CDRT15P1 (CMT1A Duplicated Region Transcript 15 pseudogene 1) is classified as a pseudogene associated with the CDRT15 gene and is located on chromosome 17[1][2]. Unlike canonical protein-coding genes, pseudogenes such as CDRT15P1 do not typically encode functional proteins but can play regulatory roles at the RNA level, such as acting as competing endogenous RNAs (ceRNAs) or influencing the expression of their parent or related genes via processes like microRNA decoy or siRNA production[3]. Evidence from recent bioinformatics studies suggests CDRT15P1 expression is associated with modulation of signaling pathways involved in longevity regulation, thyroid hormone signaling, and cellular response to DNA damage, particularly in relation to lymph node metastasis in gastric cancer[2]. Its altered expression correlates with distinct immune cell infiltration patterns and drug sensitivity profiles, notably increased sensitivity to bicalutamide in in vitro analyses, but there is no clear evidence that CDRT15P1 is itself a therapeutic target or is directly druggable. The broader significance of pseudogenes includes regulatory roles in health and disease, largely via RNA-based mechanisms, but most pseudogenes—including CDRT15P1—have not been conclusively linked to specific therapeutic mechanisms or safety concerns[2][3].\n\nCritical distinction: CDRT15P1 is a non-protein-coding pseudogene and not a receptor, enzyme, transporter, or classical drug target. It may act as a regulatory RNA influencing cancer biology but is not validated as a direct molecular target for drug discovery or intervention[2][3].

Other names

CDRT15P

Not established (correlation only; not a direct drug target, see below)